Advances in the treatment of hepatoblastoma

References:

1 Sunil BJ,Palaniappan R,Venkitaraman B,et al.Surgical Resection for Hepatoblastoma-Updated Survival Outcomes[J].J Gastrointest Cancer,2018,49(4):493-496.DOI:10.1007/s12029-017-0005-z.
2 Allan BJ,Parikh PP,Diaz S,et al.Predictors of survival and incidence of hepatoblastoma in the paediatric population[J].HPB (Oxford),2013,15(10):741-746.DOI:10.1111/hpb.12112.
3 Duan XF,Zhao Q.Adult hepatoblastoma:a review of 47 cases[J].ANZ J Surg,2018,88(1-2):E50-e54.DOI:10.1111/ans.13839.
4 中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科分会肿瘤专业组.儿童肝母细胞瘤多学科诊疗专家共识(CCCG-HB-2016)[J].中华小儿外科杂志,2017,38(10):733-739.DOI:10.3760/cma.j.issn.0253-3006.2017.10.003. Chinese Anti-Cancer Association Pediatric Committee,China Mdical Association Pediatric Onco-surgrey Group.Expert Consensus for Multidiscciplinary Management of Hepatoblastoma(CCCG-HB-2016)[J].Chin J Pediatr Surg,2017,38(10):733-739.DOI:10.3760/cma.j.issn.0253-3006.2017.10.003.
5 Fonseca A,Gupta A,Shaikh F,et al.Extreme hepatic resections for the treatment of advanced hepatoblastoma:Are planned close margins an acceptable approach?[J].Pediatr blood cancer,2018,65(2):e26820.DOI:10.1002/pbc.26820.
6 Souzaki R,Kawakubo N,Matsuura T,et al.Navigation surgery using indocyanine green fluorescent imaging for hepatoblastoma patients[J].Pediatr Surg Int,2019,35(5):551-557.DOI:10.1007/s00383-019-04458-5.
7 Yamada Y,Hoshino K,Mori T,et al.Metastasectomy of Hepatoblastoma Utilizing a Novel Overlay Fluorescence Imaging System[J].J Laparoendosc Adv Surg Tech A,2018,28(9):1152-1155.DOI:10.1089/lap.2017.0735.
8 Yamamichi T,Oue T,Yonekura T,et al.Clinical application of indocyanine green (ICG) fluorescent imaging of hepatoblastoma[J].Journal of pediatric surgery,2015,50(5):833-836.DOI:10.1016/j.jpedsurg.2015.01.014.
9 Ramos-Gonzalez G,Laquaglia M,O’Neill AF,et al.Long-term outcomes of liver transplantation for hepatoblastoma:A single-center 14-year experience[J].Pediatric transplantation,2018,e13250.DOI:10.1111/petr.13250.
10 Fuchs J,Cavdar S,Blumenstock G,et al.POST-TEXT III and IV Hepatoblastoma:Extended Hepatic Resection Avoids Liver Transplantation in Selected Cases[J].Annals of surgery,2017,266(2):318-323.DOI:10.1097/sla.0000000000001936.
11 Shi SJ,Wang DL,Hu W,et al.Ex vivo liver resection and autotransplantation with cardiopulmonary bypass for hepatoblastoma in children:A case report[J].Pediatric transplantation,2018,22(7):e13268.DOI:10.1111/petr.13268.
12 张明满,宁禹,李英存,等.自体肝移植治疗婴幼儿复杂肝母细胞瘤一例及文献复习[J].中华小儿外科杂志,2018,39(1):44-49.DOI:10.3760/cma.j.issn.0253-3006.2018.01.010. Zhang MM,Ning Y,Li YC,et al.Applicationantologous liver transplantation in complex infantile hepatoblastoma:a report of one case[J].Chin J Pediatr Surg,2018,39(1):44-49.DOI:10.3760/cma.j.issn.0253-3006.2018.01.010.
13 Namgoong JM,Choi JU,Hwang S,et al.Pediatric living donor liver transplantation with homograft replacement of retrohepatic inferior vena cava for advanced hepatoblastoma[J].Ann Hepatobiliary Pancreat Surg,2019,23(2):178-182.DOI:10.14701/ahbps.2019.23.2.178.
14 Shinkai M,Mochizuki K,Kitagawa N,et al.Usefulness of a recanalized umbilical vein for vascular reconstruction in pediatric hepatic surgery[J].Pediatr Surg Int,2016,32(6):553-558.DOI:10.1007/s00383-016-3893-2.
15 Isono K,Ohya Y,Lee KJ,et al.Pretransplant trends in alpha-fetoprotein levels as a predictor of recurrence after living donor liver transplantation for unresectable hepatoblastoma:A single-institution experience[J].Pediatric transplantation,2018,22(5):e13221.DOI:10.1111/petr.13221.
16 Van Dalen EC,Raphael MF,Caron HN,et al.Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer[J].Cochrane Database Syst Rev,2014,4(9):Cd006647.DOI:10.1002/14651858.CD006647.
17 柳龚堡,刘百慧,李凯,等.C5V作为首选化疗方案治疗肝母细胞瘤效果观察[J].中华儿科杂志,2015,53(2):119-123.DOI:10.3760/cma.j.issn.0578-1310.2015.02.011. Liu GB,Liu BH,Li K,et al.Outcome of hepatoblastoma:experience with 63 patients received chemotherapy with the regimen C5V[J].Chinese Journal of Pediatrics,2015,53(2):119-123.DOI:10.3760/cma.j.issn.0578-1310.2015.02.011.
18 Katzenstein HM,Furman WL,Malogolowkin MH,et al.Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma:A report from the Children’s Oncology Group AHEP0731 study committee[J].Cancer,2017,123(12):2360-2367.DOI:10.1002/cncr.30591.
19 常健,张语桐,王立哲,等.顺铂单剂治疗儿童肝母细胞瘤[J].中华小儿外科杂志,2011,32(10):737-740.DOI:10.3760/cma.j.issn.0253-3006.2011.10.005. Chang J,Zhang YT,Wang LZ,et al.Single-agent of cisplatin in pretreatment of hepatoblastoma[J].Chinese journal of pediatric surgery,2011,32(10):737-740.DOI:10.3760/cma.j.issn.0253-3006.2011.10.005.
20 Wei M,Yuan X.Cisplatin-induced Ototoxicity in Children With Solid Tumor[J].J Pediatr Hematol Oncol,2019,41(2):e97-e100.DOI:10.1097/mph.0000000000001282.
21 Brock PR,Maibach R,Childs M,et al.Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss[J].N Engl J Med,2018,378(25):2376-2385.DOI:10.1056/NEJMoa1801109.
22 Morcrette G,Hirsch TZ,Badour E,et al.APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures[J].Oncoimmunology,2019,8(6):e1583547.DOI:10.1080/2162402x.2019.1583547.
23 Beck A,Eberherr C,Hagemann M,et al.Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma[J].Cancer Biol Ther,2016,17(11):1168-1176.DOI:10.1080/15384047.2016.1235664.
24 Zhen N,Jin L,Ma J,et al.Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage[J].Anticancer Drugs,2018,29(8):756-766.DOI:10.1097/cad.0000000000000646.
25 姜程远,卜云芳.经导管动脉化疗栓塞术治疗巨大肝母细胞瘤疗效及安全性[J].现代仪器与医疗,2017,23(3):23-24.DOI:10.11876/mimt201703011. Jiang CY,Bu YF.Efficacy and safety of transcranial arterial chemoembolization in the treatment of giant hepatoblastoma[J].Modern instruments and medical treatment,2017,23(3):23-24.DOI:10.11876/mimt201703011.
26 Salem R,Lewandowski RJ,Mulcahy MF,et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes[J].Gastroenterology,2010,138(1):52-64.DOI:10.1053/j.gastro.2009.09.006.
27 Lungren MP,Towbin AJ,Roebuck DJ,et al.Role of interventional radiology in managing pediatric liver tumors:Part 1:Endovascular interventions[J].Pediatric radiology,2018,48(4):555-564.DOI:10.1007/s00247-018-4068-1.
28 Liu B,Zhou L,Huang G,et al.First Experience of Ultrasound-guided Percutaneous Ablation for Recurrent Hepatoblastoma after Liver Resection in Children[J].Scientific reports,2015,18(5):16805.DOI:10.1038/srep16805.
29 朱海涛,肖现民.PI3K/Akt信号通路与小儿恶性实体肿瘤研究进展[J].临床小儿外科杂志,2009,8(6):57-59.DOI:10.3969/j.issn.1671-6353.2009.06.020. Zhu HT,Xiao XM.Research progress of PI3K/Akt signaling pathway and malignant solid tumors in children[J].J Clin Ped Sur,2009,8(6):57-59.DOI:10.3969/j.issn.1671-6353.2009.06.020.
30 Molina L,Yang H,Adebayo Michael AO,et al.mTOR inhibition affects Yap1-beta-catenin-induced hepatoblastoma growth and development[J].Oncotarget,2019,10(15):1475-1490.DOI:10.18632/oncotarget.26668.
31 乔国梁.PI3K-Akt信号通路在肝母细胞瘤的作用及肝母细胞瘤预后危险因素的评估[D].北京协和医学院,2015. Qiao GL.The role of P13K-Akt Pathway in Hepatoblastoma and Evaluation of Prognostic Risk Factors of Patients with Hepatoblastoma[D].Peking union medical college,2015.
32 Zhang C,Jia X,Wang K,et al.Polyphyllin VII Induces an Autophagic Cell Death by Activation of the JNK Pathway and Inhibition of PI3K/AKT/mTOR Pathway in HepG2 Cells[J].PloS one,2016,11(1):e0147405.DOI:10.1371/journal.pone.0147405.
33 Fu H,Zhang J,Pan T,et al.miR378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR,PDGFRbeta and cRaf[J].Molecular medicine reports,2018,17(3):4581-4588.DOI:10.3892/mmr.2018.8390.
34 Cui Y,Lu P,Song G,et al.Involvement of PI3K/Akt,ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis[J].Food Chem Toxicol,2016,(92):26-37.DOI:10.1016/j.fct.2016.03.013.
35 Stafman LL,Williams AP,Marayati R,et al.PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells[J].PloS one,2019,14(4):e0214469.DOI:10.1371/journal.pone.0214469.
36 Deng S,Tang S,Zhang S,et al.Furazolidone induces apoptosis through activating reactive oxygen species-dependent mitochondrial signaling pathway and suppressing PI3K/Akt signaling pathway in HepG2 cells[J].Food Chem Toxicol,2015,(75)173-186.DOI:10.1016/j.fct.2014.11.019.
37 Perugorria MJ,Olaizola P,Labiano I,et al.Wnt-beta-catenin signalling in liver development,health and disease[J].Nat Rev Gastroenterol Hepatol,2019,16(2):121-136.DOI:10.1038/s41575-018-0075-9.
38 Indersie E,Lesjean S,Hooks KB,et al.MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling[J].Hepatology communications,2017,1(2):168-183.DOI:10.1002/hep4.1029.
39 Ellerkamp V,Lieber J,Nagel C,et al.Pharmacological inhibition of beta-catenin in hepatoblastoma cells[J].Pediatric surgery international,2013,29(2):141-149.DOI:10.1007/s00383-012-3237-9.
40 Godeke J,Maier S,Eichenmuller M,et al.Epigallocatechin-3-gallate inhibits hepatoblastoma growth by reactivating the Wnt inhibitor SFRP1[J].Nutrition and cancer,2013,65(8):1200-1207.DOI:10.1080/01635581.2013.828085.
41 Munoz M,Rosso M,Covenas R.The NK-1 receptor:a new target in cancer therapy[J].Curr Drug Targets,2011,12(6):909-921.DOI:10.2174/138945011795528796.
42 Berger M,Neth O,Ilmer M,et al.Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo[J].Journal of hepatology,2014,60(5):985-994.DOI:10.1016/j.jhep.2013.12.024.
43 Ilmer M,Garnier A,Vykoukal J,et al.Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma[J].Molecular cancer therapeutics,2015,14(12):2712-2721.DOI:10.1158/1535-7163.Mct-15-0206.
44 Garnier A,Ilmer M,Kappler R,et al.Therapeutic Innovations for Targeting Hepatoblastoma[J].Anticancer research,2016,36(11):5577-5792.DOI:10.21873/anticanres.11143.
45 Baeuerle PA,Gires O.EpCAM (CD326) finding its role in cancer[J].British journal of cancer,2007,96(3):417-423.DOI:10.1038/sj.bjc.6603494.
46 Armeanu-Ebinger S,Hoh A,Wenz J,et al.Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma[J].Oncoimmunology,2013,2(1):e22620.DOI:10.4161/onci.22620.
47 Ortiz MV,Roberts SS,Glade Bender J,et al.Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors[J].Front Oncol,2019,26(9):108.DOI:10.3389/fonc.2019.00108.
48 Tsuchiya N,Hosono A,Yoshikawa T,et al.Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors[J].Oncoimmunology,2017,7(1):e1377872.DOI:10.1080/2162402x.2017.1377872.
49 Shimizu Y,Suzuki T,Yoshikawa T,et al.Next-Generation Cancer Immunotherapy Targeting Glypican-3[J].Front Oncol,2019,10(9):248.DOI:10.3389/fonc.2019.00248.